Bristol-Myers Squibb faces revenue declines but offers long-term potential via growth drugs. Read what BMY stock has to offer ...

BMY’s robust launch portfolio, resilient free cash flow, and above-consensus growth outlook position it for outsized returns ...

Galapagos announces leadership transition. European biotechnology company Galapagos completed a significant leadership ...

AbbVie has agreed to buy Capstan Therapeutics for up to $2.1 billion, expanding its pipeline with a potential first-in-class ...

Cell and gene therapy leaders say the agency’s decision to remove the Risk Evaluation and Mitigation Strategies that had been ...

AbbVie’s $2.1 billion acquisition of Capstan Therapeutics aims to advance in vivo CAR-T therapies, transforming autoimmune ...

Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, ...

In total, there are about 50 student volunteers, along with an additional 350 volunteers registered to work on an ad hoc ...

Sanofi has doubled down on its partnership with Adagene, investing $25 million in the biotech, taking up its option on a ...

The market, which was valued at $0.85 billion in 2024, is projected to grow to $0.91 billion in 2025, representing a compound annual growth rate CAGR of 7.2%. The growth during this historic period ...

An engineered protein turns off the kind of immune cells most likely to damage tissue as part of Type-1 diabetes, hepatitis, ...